Skip to main content
SpringerLink
Log in

Traitement des lymphomes de Hodgkin localisés

  • Chapter
Actualités thérapeutiques dans les lymphomes

  • 565 Accesses

Résumé

Historiquement, la maladie de Hodgkin a été la première maladie maligne curable. Des guérisons ont été obtenues après radiothérapie dans des formes localisées, sous réserve de l’utilisation d’une dose curatrice d’au moins 35/40 Grays (Gy) à raison de 10 Gy par semaine, et surtout, par des irradiations étendues comprenant les territoires adjacents.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Lister TA, Crowther D, Sutcliffe SB, et al. (1989) Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 7(11): 1630–6

    PubMed  CAS  Google Scholar 

  2. Specht (1996) Prognostic Factors in Hodgkin’s Disease. Semin Radiat Oncol 6(3): 146–61

    Article  PubMed  Google Scholar 

  3. Tubiana M, Henry-Amar M, van der Werf-Messing B, et al. (1985) A multivariate analysis of prognostic factors in early stage Hodgkin’s disease. Int J Radiat Oncol Biol Phys 11(1): 23–30

    Article  PubMed  CAS  Google Scholar 

  4. Specht L, Raemaekers J (2007) Do we need an early unfavorable (intermediate) stage of Hodgkin’s lymphoma? Hematol Oncol Clin North Am 21(5): 881–96

    Article  PubMed  Google Scholar 

  5. Noordijk EM, Carde P, Dupouy N, et al. (2006) Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 24(19): 3128–35

    Article  PubMed  Google Scholar 

  6. Hoppe RT, Coleman CN, Cox RS, et al. (1982) The management of stage I–II Hodgkin’s disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 59(3): 455–65

    PubMed  CAS  Google Scholar 

  7. Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al. (2002) The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38(Suppl 4): S107–13

    Article  PubMed  Google Scholar 

  8. Tubiana M, Henry-Amar M, Carde P, et al. (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood 73(1): 47–56

    PubMed  CAS  Google Scholar 

  9. Tubiana M, Henry-Amar M, Hayat M, et al. (1979) Long-term results of the EORTC randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin’s disease. Eur J Cancer 15(5): 645–57

    PubMed  CAS  Google Scholar 

  10. Tubiana M, Hayat M, Henry-Amar M, et al. (1981) Five-year results of the EORTC randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin’s disease. Eur J Cancer 17(3): 355–63

    PubMed  CAS  Google Scholar 

  11. Carde P, Burgers JM, Henry-Amar M, et al. (1988) Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 6(2): 239–52

    PubMed  CAS  Google Scholar 

  12. Carde P, Hagenbeek A, Hayat M, et al. (1993) Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin’s disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11(11): 2258–72

    PubMed  CAS  Google Scholar 

  13. Dühmke E, Franklin J, Pfreundschuh M, et al. (2001) Low-dose radiation is sufficient for the noninvolved extended-field treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 19(11): 2905–14

    PubMed  Google Scholar 

  14. Noordijk E, Carde P, Hagenbeek A, et al. (1997) Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I–II Hodgkin’s disease six-year results of the EORTC/GPMC controlled clinical trials H7-VF, H7-F and H7-U. Int J Radiat Oncol Biol Phys 39(2): 173

    Article  Google Scholar 

  15. Specht L, Gray RG, Clarke MJ, Peto R (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. J Clin Oncol 16(3): 830–43

    PubMed  CAS  Google Scholar 

  16. Horwich A, Specht L, Ashley S (1997) Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 33(6): 848–53

    Article  PubMed  CAS  Google Scholar 

  17. Ng AK, Bernardo MP, Weller E, et al. (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol 20(8): 2101–8

    Article  PubMed  Google Scholar 

  18. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, et al. (2003) Long-term causespecific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 21(18): 3431–9

    Article  PubMed  Google Scholar 

  19. Favier O, Heutte N, Stamatoullas-Bastard A, et al. (2009) Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer 115(8): 1680–91

    Article  PubMed  Google Scholar 

  20. Canellos GP, Anderson JR, Propert KJ, et al. (1992) Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327(21): 1478–84

    Article  PubMed  CAS  Google Scholar 

  21. Press OW, LeBlanc M, Lichter AS, et al. (2001) Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 19(22): 4238–44

    PubMed  CAS  Google Scholar 

  22. Engert A, Franklin J, Eich HT, et al. (2007) Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 25(23): 3495–3502

    Article  PubMed  CAS  Google Scholar 

  23. Fermé C, Eghbali H, Meerwaldt JH, et al. (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med 357(19): 1916–27

    Article  PubMed  Google Scholar 

  24. Engert A, Plütschow A, Eich HT, et al. (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363(7): 640–52

    Article  PubMed  CAS  Google Scholar 

  25. Horning SJ, Hoppe RT, Breslin S, et al. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20(3): 630–7

    Article  PubMed  Google Scholar 

  26. Arakelyan N, Jais J-P, Delwail V, et al. (2010) Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial. Cancer 116(17): 4054–62

    Article  PubMed  Google Scholar 

  27. Noordijk E, Thomas J, Fermé C, et al. (2005) First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL). J Clin Oncol 23(16S): 6505

    Google Scholar 

  28. Engert A, Schiller P, Josting A, et al. (2003) Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21(19): 3601–8

    Article  PubMed  Google Scholar 

  29. Bonadonna G, Bonfante V, Viviani S, et al. (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22(14): 2835–41

    Article  PubMed  Google Scholar 

  30. Girinsky T, van der Maazen R, Specht L, et al. (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79(3): 270–7

    Article  PubMed  Google Scholar 

  31. Shahidi M, Kamangari N, Ashley S, et al. (2006) Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol 78(1): 1–5

    Article  PubMed  Google Scholar 

  32. Campbell BA, Voss N, Pickles T, et al. (2008) Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol 26(32): 5170–4

    Article  PubMed  Google Scholar 

  33. Longo DL, Glatstein E, Duffey PL, et al. (1991) Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin’s disease: seven-year results of a prospective randomized trial. J Clin Oncol 9(6): 906–17

    PubMed  CAS  Google Scholar 

  34. Biti GP, Cimino G, Cartoni C, et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I–IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 10(3): 378–82

    PubMed  CAS  Google Scholar 

  35. Meyer RM, Gospodarowicz MK, Connors JM, et al. (2012) ABVD alone versus radiation-based therapy in limited-stage Hodgkin’s lymphoma. N Engl J Med 366(5): 399–408

    Article  PubMed  CAS  Google Scholar 

  36. Straus DJ, Portlock CS, Qin J, et al. (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 104(12): 3483–9

    Article  PubMed  CAS  Google Scholar 

  37. Bonadonna G, Zucali R, Monfardini S, et al. (1975) Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36(1): 252–9

    Article  PubMed  CAS  Google Scholar 

  38. Canellos GP, Niedzwiecki D (2002) Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 346(18): 1417–8

    Article  PubMed  Google Scholar 

  39. Duggan DB, Petroni GR, Johnson JL, et al. (2003) Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial. J Clin Oncol 21(4): 607–14

    Article  PubMed  CAS  Google Scholar 

  40. Le Maignan C, Desablens B, Delwail V, et al. (2004) Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood 103(1): 58–66

    Article  PubMed  Google Scholar 

  41. L Eich HT, Diehl V, Görgen H, et al. (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28(27): 4199–4206

    Article  PubMed  Google Scholar 

  42. Wasserman TH, Petroni GR, Millard FE, et al. (1999) Sequential chemotherapy (etoposide, vinblastine, and doxorubicin) and subtotal lymph node radiation for patients with localized Hodgkin disease and unfavorable prognostic features: A phase II Cancer and Leukemia Group B Study (9051). Cancer 86(8): 1590–5

    Article  PubMed  CAS  Google Scholar 

  43. Hasenclever D, Loeffler M, Diehl V (1996) Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin’s disease. German Hodgkin’s Lymphoma Study Group. Ann Oncol 7(Suppl 4): 95–8

    Article  PubMed  Google Scholar 

  44. von Tresckow B, Plütschow A, Fuchs M, et al. (2012) Dose-intensification in early unfavorable Hodgkin’s lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology (doi: 10.1200/JCO.2011.38.5807)

    Google Scholar 

  45. Anselmo AP, Cavalieri E, Osti FM, et al. (2004) Intermediate stage Hodgkin’s disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy. Anticancer Res 24(6): 4045–50

    PubMed  CAS  Google Scholar 

  46. Aleman BMP, Raemaekers JMM, Tirelli U, et al. (2003) Involved-field radiotherapy for advanced Hodgkin’s lymphoma. N Engl J Med 348(24): 2396–2406

    Article  PubMed  Google Scholar 

  47. Diehl V, Franklin J, Pfreundschuh M, et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348(24): 2386–95

    Article  PubMed  CAS  Google Scholar 

  48. Kobe C, Dietlein M, Franklin J, et al. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 112(10): 3989–94

    Article  PubMed  CAS  Google Scholar 

  49. Laskar S, Gupta T, Vimal S, et al. (2004) Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 22(1): 62–8

    Article  PubMed  CAS  Google Scholar 

  50. Pavlovsky S, Maschio M, Santarelli MT, et al. (1988) Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I–II Hodgkin’s disease. J Natl Cancer Inst 80(18): 1466–73

    Article  PubMed  CAS  Google Scholar 

  51. Hutchings M, Loft A, Hansen M, et al. (2006) Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 91(4): 482–9

    PubMed  Google Scholar 

  52. Gallamini A, Hutchings M, Rigacci L, et al. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25(24): 3746–52

    Article  PubMed  CAS  Google Scholar 

  53. Hutchings M, Mikhaeel NG, Fields PA, et al. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 16(7): 1160–8

    Article  PubMed  CAS  Google Scholar 

  54. Hutchings M, Loft A, Hansen M, et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107(1): 52–9

    Article  PubMed  CAS  Google Scholar 

  55. Kasamon YL, Wahl RL (2008) FDG PET and risk-adapted therapy in Hodgkin’s and non-Hodgkin’s lymphoma. Curr Opin Oncol 20(2): 206–19

    Article  PubMed  Google Scholar 

  56. André MP, Reman O, Fédérico M, et al. (2009) First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin’s Lymphoma, for the Groupe d’Étude Des Lymphomes De l’Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL). Blood 114: 44–5

    Google Scholar 

  57. Heutte N, Flechtner HH, Mounier N, et al. (2009) Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomized controlled trial. Lancet Oncol 10(12): 1160–70

    Article  PubMed  Google Scholar 

  58. Brepoels L, Stroobants S (2008) PET scanning and prognosis in Hodgkin’s lymphoma. Curr Opin Oncol 20(5): 509–16

    Article  PubMed  Google Scholar 

  59. Aviles A, Delgado S (1998) A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin’s disease with bulky disease. Clin Lab Haematol 20(2): 95–9

    Article  PubMed  CAS  Google Scholar 

  60. Nachman JB, Sposto R, Herzog P, et al. (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol 20(18): 3765–71

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’hématologie clinique, CHU de Nantes, 1, place Alexis Ricordeau, 44093, Nantes Cedex 1, France

    T. Gastinne

Authors
  1. T. Gastinne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Gastinne .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Paris

About this chapter

Cite this chapter

Gastinne, T. (2013). Traitement des lymphomes de Hodgkin localisés. In: Actualités thérapeutiques dans les lymphomes. Springer, Paris. https://doi.org/10.1007/978-2-8178-0371-5_1

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0371-5_1

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0370-8

  • Online ISBN: 978-2-8178-0371-5

Publish with us

Policies and ethics

Search

Navigation